Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 58 points (-0.4%) at 15,461 as of Wednesday, Aug. 7, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 785 issues advancing vs. 2,161 declining with 94 unchanged. The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.4%. Top gainers within the industry include Santarus ( SNTS), up 8.5%, Biomarin Pharmaceutical ( BMRN), up 2.1%, Celgene Corporation ( CELG), up 1.4%, Amgen ( AMGN), up 1.8% and Sanofi ( SNY), up 0.8%. A company within the industry that fell today was Biogen Idec ( BIIB), up 0.8%. TheStreet would like to highlight 5 stocks pushing the industry higher today: 5. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.30 (0.6%) to $51.63 on average volume. Thus far, 1.2 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $51.57-$52.01 after having opened the day at $51.63 as compared to the previous trading day's close of $51.33. GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $128.1 billion and is part of the health care sector. Shares are up 19.3% year to date as of the close of trading on Tuesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold. TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.